Here’s another one to add to The Graveyard (dead, just not buried yet). Virtually unknown public company SCOLR Pharma has axed two of its board members.

The company, which dabbles in controlled release technology, has about $6M+ left in cash and without additional financing, will not see the end of the year. Management also said that its independent audit for the year “included an audit opinion that expressed doubt about the company’s ability to continue as a going concern.”

Yeah yeah.

The company’s lead program is a controlled-release version of Ibuprofen (Advil basically) which offers no real advantages other than being able to take one pill every 12 hours vs. three pills. Scolr has already completed a pivotal Phase 3 study, but still requires an actual use study before it can file a 505b2 NDA in 2010. Also, their pseudoephedrine CR program received a complete response from the FDA in January so things are definitely not looking good.

Just talking about this company’s technology puts me to sleep - nothing advantageous or exciting.

Guys, bc you axed board members and not employees (17 full time) we’ll end here and be nice

SCOLR Pharma – the newest addition to The Graveyard!

Image from steeltoedclownboot

Related Posts